The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMicrosaic Regulatory News (MSYS)

Share Price Information for Microsaic (MSYS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.00
Bid: 0.95
Ask: 1.05
Change: 0.00 (0.00%)
Spread: 0.10 (10.526%)
Open: 1.00
High: 1.00
Low: 1.00
Prev. Close: 1.00
MSYS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DeepVerge plc debtor

18 Apr 2023 07:59

RNS Number : 5723W
Microsaic Systems plc
18 April 2023
 

18 April 2023

 

Microsaic Systems plc

 

("Microsaic" or the "Company")

 

DeepVerge plc ("DeepVerge") debtor

 

 

Further to yesterday's announcement by DeepVerge[1], Microsaic (AIM: MSYS) notes that material sums are owed by DeepVerge group companies to Microsaic, totalling approximately £1.4 million as at today's date which largely relates to the supply of goods and services recognised as revenues for the financial year ended 31 December 2022 ("FY22"). The balance outstanding has reduced from approximately £1.5 million at 31 December 2022 following receipt of certain payments from DeepVerge.

 

A settlement plan has been proposed by DeepVerge to Microsaic, the terms of which are substantially agreed subject to clarification in respect of suitable potential security for the balances due. DeepVerge has made an initial payment in line with that plan, the value of which exceeds £0.1 million. In addition, Microsaic has continued to supply services to DeepVerge during 2023, and all amounts arising during the current financial year continue to be received by Microsaic under normal 30-day terms, in line with commercial agreements between the two parties.

 

Microsaic has cash of £0.8 million as of 17 April 2023 and is due to receive R&D tax credits in respect of 2021 and 2022 totalling circa £0.5 million, as well as the outstanding DeepVerge balance of £1.4 million. Although the first quarter of trading in the current year has started slowly, Microsaic has a growing sales pipeline currently worth in excess of £2 milllion, over 90% of which is from customers or distribution channels other than DeepVerge. This reflects the continual sales effort to cultivate and expand the Company's relationships with current customers, while also actively pursuing new business opportunities. A mixture of prospective repeat sales and new revenue streams are therefore expected to support Microsaic's continuing sales progress in 2023 and beyond.

Microsaic expects to release its audited financial results for the year ended 31 December 2022 (the "FY22 Results") during the first half of May 2023. The phasing and quantities of receipts from DeepVerge in relation to this historic commercial debt will be subject to further discussion with the Company's auditors, and appropriate disclosures will be included within the FY22 Results. 

 

Enquiries:

 

Microsaic Systems plc

+44 (0) 734 0055 648

Gerry Brandon, Acting Executive Chairman

 

 

Singer Capital Markets (Nominated Adviser & Joint Broker)

+44 (0)20 7496 3000

Aubrey Powell / George Tzimas

 

 

Turner Pope Investments (TPI) Limited (Joint Broker)

Andy Thacker / James Pope

+44 (0) 20 3657 0050

 

 

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information as stipulated under the UK version of the market abuse regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

About Microsaic Systems

Microsaic floated on AIM in 2011 to develop and commercialise micro-engineering chip-based mass spectrometry equipment. Having invested c. £30m over 20 years of development, Microsaic has a robust and innovative patent portfolio in cutting-edge technology designed and developed for "Industry 4.0" application. Microsaic serves markets in Human Health, Environmental Health and Diversified Industries. Microsaic's system solutions enable analytical detection and characterisation at the point-of-need, whether within a conventional laboratory setting, or within a bioprocessing facility for continuous MS detection data at multiple steps in the process workflow.

 

Microsaic's products and systems are commercially available through global markets via a network of regional and local partners, targeting its core laboratory, manufacturing and point of need applications

 

 


[1] https://www.londonstockexchange.com/news-article/DVRG/2022-revenue-update-revision/15917630

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCKZGMDVRRGFZG
Date   Source Headline
11th Aug 20209:30 amRNSForm 8.5 (EPT/RI)
10th Aug 20204:33 pmBUSForm 8.3 - Microsaic Systems
10th Aug 202010:08 amRNSForm 8.5 (EPT/RI)
7th Aug 20204:59 pmRNSForm 8.3 - Microsaic Systems PLC
7th Aug 20209:14 amRNSForm 8.5 (EPT/RI)
6th Aug 202012:07 pmRNSForm 8.5 (EPT/RI)
5th Aug 202010:04 amRNSForm 8.5 (EPT/RI)
4th Aug 20202:31 pmRNSForm 8.3 - Microsaic Systems PLC
4th Aug 202011:39 amRNSForm 8.5 (EPT/RI)
3rd Aug 20201:54 pmRNSForm 8.3 - Microsaic Systems plc
3rd Aug 202011:24 amRNSForm 8.5 (EPT/RI)
31st Jul 20204:06 pmRNSForm 8 (OPD) Microsaic Systems plc
31st Jul 20201:43 pmRNSForm 8.3 - Microsaic Systems plc
31st Jul 20209:37 amRNSForm 8.5 (EPT/RI)
31st Jul 20209:11 amRNSForm 8.3 - Microsaic Systems plc
30th Jul 20204:03 pmRNSParkwalk Advisors: Form 8.3- Microsaic Systems plc
30th Jul 202011:47 amRNSForm 8.5 (EPT/RI)
29th Jul 20205:48 pmGNWForm 8.3 - Microsaic Systems plc
29th Jul 202012:00 pmRNSForm 8.3 - Microsaic Systems plc
29th Jul 20207:00 amRNSStrategic Review and Formal Sale Process
25th Jun 20203:16 pmRNSResult of AGM
1st Jun 20207:00 amRNSPosting of Annual Report and Notice of AGM
7th May 20207:00 amRNSCOVID-19 Update
9th Mar 20207:00 amRNSFinal Results
3rd Mar 20207:00 amRNSAppointment of WH Ireland as Joint Broker
26th Feb 20207:00 amRNSGlobal collaboration agreement with Axcend Corp
16th Jan 20207:00 amRNSPre-close Trading Update
16th Dec 20197:00 amRNSMicrosaic collaborates with the CPI
6th Dec 20194:35 pmRNSPrice Monitoring Extension
5th Dec 20199:05 amRNSSecond Price Monitoring Extn
5th Dec 20199:00 amRNSPrice Monitoring Extension
5th Dec 20197:00 amRNSExclusive Japan Distribution Agreement
13th Nov 20194:41 pmRNSSecond Price Monitoring Extn
13th Nov 20194:35 pmRNSPrice Monitoring Extension
26th Sep 20194:35 pmRNSPrice Monitoring Extension
23rd Sep 20197:00 amRNSInterim Results
4th Sep 20197:00 amRNSNotice of Results
12th Jun 20191:38 pmRNSAward of options
7th Jun 20197:00 amRNSDistribution Agreement with CM Corporation Ltd.
3rd Jun 20197:00 amRNSCost and time savings in manufacture of biologics
16th May 20192:06 pmRNSBoard Change
14th May 201912:00 pmRNSResult of AGM
14th May 201911:05 amRNSSecond Price Monitoring Extn
14th May 201911:00 amRNSPrice Monitoring Extension
14th May 20197:00 amRNSAGM Statement
2nd May 20197:00 amRNSDeepened collaboration with Chinese partner
12th Apr 20197:00 amRNSNotice of AGM and Posting of Annual Report
18th Mar 20197:00 amRNSOEM Agreement
11th Mar 20197:00 amRNSFinal Results
5th Mar 20197:00 amRNSMSYS jointly publishes bioprocessing data with MIT

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.